Literature DB >> 18082317

Core biopsies of renal tumors: a study on diagnostic accuracy, interobserver, and intraobserver variability.

Intan Kümmerlin1, Fiebo ten Kate, Frank Smedts, Thomas Horn, Ferran Algaba, Isabel Trias, J de la Rosette, M Pilar Laguna.   

Abstract

OBJECTIVE: The diagnostic accuracy of in-bench core biopsies (CBs) from renal masses, and the interobserver and intraobserver variability in pathological subtyping of renal tumors were assessed.
METHODS: We performed two CBs in 62 consecutive renal masses suspected for renal cell carcinoma (RCC), obtained after radical or partial nephrectomy and, in one case, after autopsy. Routine hematoxylin-eosin (HE)-stained sections from each CB were evaluated by five pathologists on two occasions. The surgical specimen was the reference standard. Diagnostic accuracy and the generalized kappa for intraobserver and interobserver agreement were calculated.
RESULTS: Five tumors were benign and 57 malignant. Eight percent to 16% of the CBs were considered inadequate for diagnosis. In 0-8% of the cases, the pathologist could not discriminate between a benign or malignant tumor. Overall accuracy ranged from 77% to 90%. Sensitivity (79-100%) and positive predictive value (100%) were high with narrow 95% confidence interval (95%CI). Specificity (100%) was high but negative predictive value (29%-100%) varied, with wide 95% CI. Interobserver agreement was fair to almost perfect (kappa=-0.010 to 0.830) for the different subtypes. In 64-81% of the CBs, the subtype was correctly classified. Intraobserver agreement was substantial (mean kappa=0.628) for all pathologists.
CONCLUSION: Diagnostic accuracy of CBs was high, with a diagnostic yield varying between 84% and 92%. Pathological subtyping of CBs was highly reproducible with the exception of the chromophobe renal cell carcinoma, which was problematic on HE-stained sections only.

Entities:  

Mesh:

Year:  2007        PMID: 18082317     DOI: 10.1016/j.eururo.2007.11.054

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

1.  Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.

Authors:  Adeboye O Osunkoya; Qiqin Yin-Goen; John H Phan; Richard A Moffitt; Todd H Stokes; May D Wang; Andrew N Young
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

Review 2.  Evaluation of renal masses with contrast-enhanced ultrasound.

Authors:  S Houtzager; H Wijkstra; J J M C H de la Rosette; M P Laguna
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

3.  Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.

Authors:  Frank Chen; Hannu Huhdanpaa; Bhushan Desai; Darryl Hwang; Steven Cen; Andy Sherrod; Jean-Christophe Bernhard; Mihir Desai; Inderbir Gill; Vinay Duddalwar
Journal:  Springerplus       Date:  2015-02-10

4.  What is the added value of combined core biopsy and fine needle aspiration in the diagnostic process of renal tumours?

Authors:  K Barwari; I P Kummerlin; F J ten Kate; F Algaba; I Trias; H Wijkstra; J J De la Rosette; P Laguna
Journal:  World J Urol       Date:  2011-05-28       Impact factor: 4.226

5.  Tumor doubling time of renal cell carcinoma measured by CT.

Authors:  Rajendra Nerli; Shishir Devaraju; Murigendra B Hiremath; Ajay Kumar Guntaka; Pravin Patne; Neeraj Dixit
Journal:  Indian J Urol       Date:  2014-04

6.  Reinventing diagnostics for personalized therapy in oncology.

Authors:  Diponkar Banerjee
Journal:  Cancers (Basel)       Date:  2010-06-02       Impact factor: 6.639

7.  A miRNA-based classification of renal cell carcinoma subtypes by PCR and in situ hybridization.

Authors:  Ashley Di Meo; Rola Saleeb; Samantha J Wala; Heba W Khella; Qiang Ding; Haiyan Zhai; Kalra Krishan; Adriana Krizova; Manal Gabril; Andrew Evans; Fadi Brimo; Maria D Pasic; Antonio Finelli; Eleftherios P Diamandis; George M Yousef
Journal:  Oncotarget       Date:  2017-12-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.